Mutational impact of culturing human pluripotent and adult stem cells
Ewart KuijkiD, Myrthe JageriD, Bastiaan R. Van der RoestiD, Mauro D. LocatiiD, Arne van HoeckiD, Jerome KorzeliusiD, Roel JansseniD, Nicolle J.M. BesselinkiD, Sander BoymansiD, Ruben van BoxteliD, Edwin P. J. G. CuppeniD
Abstract
Genetic changes acquired during in vitro culture pose a potential risk for the successful application of stem cells in regenerative medicine. To assess mutation accumulation risks induced by culturing, we determined genetic aberrations in individual human induced pluripotent stem cells (iPS cells) and adult stem cells (ASCs) by whole genome sequencing analyses. Individual iPS cells, intestinal ASCs and liver ASCs accumulated 3.5{+/-}0.5, 7.2{+/-}1.0 and 8.4{+/-}3.6 base substitutions per population doubling, respectively. The annual in vitro mutation accumulation rate of ASCs adds up to [~]1600 base pair substitutions, which is [~]40-fold higher than the in vivo rate of [~]40 base pair substitutions per year. Mutational analysis revealed a distinct in vitro induced mutational signature that is irrespective of stem cell type and distinct from the in vivo mutational signature. This in vitro signature is characterized by C to A changes that have previously been linked to oxidative stress conditions. Additionally, we observed stem cell-specific mutational signatures and differences in transcriptional strand bias, indicating differential activity of DNA repair mechanisms between stem cell types in culture. We demonstrate that the empirically defined mutation rates, spectra, and genomic distribution enable risk assessment by modelling the accumulation of specific oncogenic mutations during typical in vitro expansion, manipulation or screening experiments using human stem cells. Taken together, we have here for the first time accurately quantified and characterized in vitro mutation accumulation in human iPS cells and ASCs in a direct comparison. These results provide insights for further optimization of culture conditions for safe in vivo utilization of these cell types for regenerative purposes.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 124
- FWCI
- 6.32
- Field percentile
- top 2%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Insights into the mutational burden of human induced pluripotent stem cells using an integrative omics approach
Matteo D’Antonio, Paola Benaglio, … Kelly A. Frazer·Cell ReportsPeer-reviewed·Jul 1, 2018
- De novo cancer mutations frequently associate with recurrent chromosomal abnormalities during long-term human pluripotent stem cell culture
Diana Al Delbany, Manjusha S. Ghosh, … Claudia Spits·CellsPeer-reviewed·Aug 21, 2024
- Substantial somatic genomic variation and selection for BCOR mutations in human induced pluripotent stem cells
Foad J. Rouhani, Xueqing Zou, … Serena Nik‐Zainal·Nature GeneticsPeer-reviewed·Aug 11, 2022
- The mutational landscape of human somatic and germline cells
Luiza Moore, Alex Cagan, … Raheleh Rahbari·Yearbook of pediatric endocrinologyPeer-reviewed·Sep 12, 2022
- Nucleosides rescue replication-mediated genome instability of human pluripotent stem cells
J. A. Halliwell, T. J. R. Frith, … P. W. Andrews·bioRxiv·Nov 23, 2019
- A comprehensive atlas of somatic mutation rates and mutational signatures in normal human cells
My H. Pham, Luke M. R. Harvey, … Michael R. Stratton·bioRxiv·Aug 29, 2026